605680-66-8

Basic information

• Product Name: methyl 2-diazo-3(4-chlorophenyl)propanoate
• Synonyms: methyl 2-diazo-3(4-chlorophenyl)propanoate
• CAS NO: 605680-66-8
• Molecular Weight: 224.647
• Mol File: 605680-66-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 2-diazo-3(4-chlorophenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-diazo-3(4-chlorophenyl)propanoate(605680-66-8)
• EPA Substance Registry System: methyl 2-diazo-3(4-chlorophenyl)propanoate(605680-66-8)

Safety Data

• Hazardous Substances Data: 605680-66-8(Hazardous Substances Data)

Upstream product

• 622-95-7 4-chlorobenzyl bromide 
• 15028-44-1 DL-phenylalanine methyl ester 
• 23434-96-0 H₆₉/17 

Downstream Products

• 1399359-57-9 C₁₆H₂₂ClNO₃ 
• 605680-68-0 4-(4-chlorophenyl)-3-cyclobutylmethoxybutan-2-one 
• 605680-65-7 2-amino-4-(4-chlorophenyl)-3-cyclobutylmethoxybutane 
• 1186002-23-2 methyl (E)-2-hydrazono-3-(4-chlorophenyl)propionate 
• 1144503-30-9 dimethyl 3,4-bis(4-chlorophenyl)-1H-pyrrole-2,5-dicarboxylate 
• 605680-67-9 methyl 3-(4-chlorophenyl)-2-cyclobutylmethoxypropanoate 

Relevant articles and documents

Catalytic Asymmetric Homologation of Ketones with α-Alkyl α-Diazo Esters

The homologation of ketones with diazo compounds is a useful strategy to synthesize one-carbon chain-extended acyclic ketones or ring-expanded cyclic ketones. However, the asymmetric homologation of acyclic ketones with α-diazo esters remains a challenge due to the lower reactivity and complicated selectivity. Herein, we report the enantioselective catalytic homologation of acetophenone and related derivatives with α-alkyl α-diazo esters utilizing a chiral scandium(III) N,N′-dioxide as the Lewis acid catalyst. This reaction supplies a highly chemo-, regio-, and enantioselective pathway for the synthesis of optically active β-keto esters with an all-carbon quaternary center through highly selective alkyl-group migration of the ketones. Moreover, the ring expansion of cyclic ketones was accomplished under slightly modified conditions, affording a series of enantioenriched cyclic β-keto esters. Density functional theory calculations have been carried out to elucidate the reaction pathway and possible working models that can explain the observed regio- and enantioselectivity.

SUBSTITUTED SULFONAMIDES

The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.